The presence of resistance mutations to protease and polymerase inhibitors in Hepatitis C virus sequences from the Los Alamos databank.
about
Geneticin Stabilizes the Open Conformation of the 5' Region of Hepatitis C Virus RNA and Inhibits Viral ReplicationMechanisms of Hepatitis C Viral Resistance to Direct Acting AntiviralsResistance of Hepatitis C Virus to Inhibitors: Complexity and Clinical ImplicationsInhibitors of the Hepatitis C Virus Polymerase; Mode of Action and ResistanceMouse Systems to Model Hepatitis C Virus Treatment and Associated ResistanceGenetic Barrier to Direct Acting Antivirals in HCV Sequences Deposited in the European DatabankHigh-resolution hepatitis C virus subtyping using NS5B deep sequencing and phylogeny, an alternative to current methodsNaturally occurring drug resistance associated variants to hepatitis C virus direct-acting antiviral agents in treatment-naive HCV genotype 1b-infected patients in China.Naturally occurring dominant drug resistance mutations occur infrequently in the setting of recently acquired hepatitis C.Two Distinct Hepatitis C Virus Genotype 1a Clades Have Different Geographical Distribution and Association With Natural Resistance to NS3 Protease Inhibitors.Comprehensive Screening for Naturally Occurring Hepatitis C Virus Resistance to Direct-Acting Antivirals in the NS3, NS5A, and NS5B Genes in Worldwide Isolates of Viral Genotypes 1 to 6Substitutions at NS3 Residue 155, 156, or 168 of Hepatitis C Virus Genotypes 2 to 6 Induce Complex Patterns of Protease Inhibitor ResistanceDirect-acting Antiviral Agents Resistance-associated Polymorphisms in Chinese Treatment-naïve Patients Infected with Genotype 1b Hepatitis C Virus.Polymorphisms and resistance mutations of hepatitis C virus on sequences in the European hepatitis C virus database.Naturally occurring resistance mutations to inhibitors of HCV NS5A region and NS5B polymerase in DAA treatment-naïve patients.Hepatitis C virus genetic variability and the presence of NS5B resistance-associated mutations as natural polymorphisms in selected genotypes could affect the response to NS5B inhibitors.Natural prevalence of hepatitis C virus (HCV) variants resistant to protease and polymerase inhibitors in patients infected with HCV genotype 1 in Tunisia.In Vitro Activity of Simeprevir against Hepatitis C Virus Genotype 1 Clinical Isolates and Its Correlation with NS3 Sequence and Site-Directed Mutants.Associations between responses to interferon therapy and genetic variation in interleukin-28B and the core region of hepatitis C virus genotype 3a.Baseline hepatitis C virus (HCV) NS3 polymorphisms and their impact on treatment response in clinical studies of the HCV NS3 protease inhibitor faldaprevir.Protease inhibitor resistance mutations in untreated Brazilian patients infected with HCV: novel insights about targeted genotyping approaches.The presence of additional resistance-related polymorphisms to NS3 protease inhibitors in hepatitis C virus sequences from the Los Alamos databank.Prevalence of hepatitis C virus-resistant association substitutions to direct-acting antiviral agents in treatment-naïve hepatitis C genotype 1b-infected patients in western China.Molecular characterization of hepatitis C virus in end-stage renal disease patients under hemodialysis.Characterization of NS5A and NS5B Resistance-Associated Substitutions from Genotype 1 Hepatitis C Virus Infected Patients in a Portuguese Cohort.Natural polymorphisms in the resistance associated sites of HCV-G1 NS5B domain and correlation with geographic origin of HCV isolates
P2860
Q26700112-620D2684-F410-4CA7-BDDA-0F0C4EEDC53EQ26773321-B01F6026-DCA4-4711-8D97-50B1C9114E2CQ26777408-D19F2D9A-17C5-46C2-BE43-3ED853CC9292Q26783056-D09A9A9F-0F97-4977-916B-2D67CCA98C71Q27469038-FBDAEC4C-001E-4926-9C06-B5A1B46A864EQ28553430-64B8C05C-EAF9-4254-9E6A-3C9E384D4219Q28652352-B66DADA6-C7E4-4817-98D7-043C0035645AQ33672648-879686FE-9DA4-41E4-A319-64E521932865Q35061753-968BC6C6-3AED-4C58-80D3-3395E72CBEB6Q35880497-489CC7E8-3319-46F9-A74B-8BD9CD24C129Q35917596-69599C1E-7568-4E7C-AA27-574A1B2038D8Q36290778-FCBA376F-9A23-4DC2-8356-4F09FC62C743Q36531731-E30A506C-8BC5-48C5-BCE8-9A6D30F26325Q37373261-BBEFF26F-EAA1-4B9D-8B9C-F9A26AEAC961Q37426527-769F46EA-C444-423C-ACB5-E2DB6A7D6274Q38849307-A0CC6AAF-1DFF-4E12-AF11-B18F3E1CCE21Q38864459-AB8886E0-1D2B-4DF2-A025-F87583FFAB5AQ40988716-881E4229-8B74-4D03-92F7-6A086A936D65Q41291382-720B1035-73FA-4B59-843E-F1D700F07528Q41907710-24F48B16-59DA-4FE6-8BF4-5EA794D1AC0FQ42205040-67EAF9CF-4493-4AF7-9CB6-47B044A194EBQ42999029-26301BEF-D6C0-4DC3-8F76-DB522FB6AADFQ45324124-0B656FD6-BE29-49D4-8431-B84457309994Q45325775-46E20A94-BE77-4C67-BC4C-0D01362CA35EQ53690933-9D8E9E81-A675-405A-A55C-C4BD6FC284FFQ58725182-C049A8B8-C008-43EA-9C06-94719BEDD391
P2860
The presence of resistance mutations to protease and polymerase inhibitors in Hepatitis C virus sequences from the Los Alamos databank.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
The presence of resistance mut ...... from the Los Alamos databank.
@en
The presence of resistance mut ...... from the Los Alamos databank.
@nl
type
label
The presence of resistance mut ...... from the Los Alamos databank.
@en
The presence of resistance mut ...... from the Los Alamos databank.
@nl
prefLabel
The presence of resistance mut ...... from the Los Alamos databank.
@en
The presence of resistance mut ...... from the Los Alamos databank.
@nl
P2093
P2860
P356
P1476
The presence of resistance mut ...... from the Los Alamos databank.
@en
P2093
A T L Queiroz
D F C Mazo
E F da Silva
F J Carrilho
I M V G de Carvalho
M G Pessoa
R J Carvalho-Filho
P2860
P304
P356
10.1111/JVH.12051
P577
2013-02-06T00:00:00Z